DiaMedica Therapeutics (NASDAQ:DMAC) Share Price Crosses Below 50-Day Moving Average – Time to Sell?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC – Get Free Report) crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $8.35 and traded as low as $7.99. DiaMedica Therapeutics shares last traded at $8.02, with a volume of 375,716 shares.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DMAC. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of DiaMedica Therapeutics in a research note on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 14th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, DiaMedica Therapeutics has an average rating of “Hold” and an average price target of $12.00.

Get Our Latest Analysis on DMAC

DiaMedica Therapeutics Trading Up 2.6%

The firm’s fifty day moving average price is $8.38 and its 200-day moving average price is $7.20. The firm has a market cap of $444.07 million, a price-to-earnings ratio of -10.83 and a beta of 0.95.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). On average, sell-side analysts expect that DiaMedica Therapeutics, Inc. will post -0.86 earnings per share for the current year.

Institutional Trading of DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Private Capital Management LLC lifted its holdings in shares of DiaMedica Therapeutics by 20.0% in the 3rd quarter. Private Capital Management LLC now owns 60,000 shares of the company’s stock valued at $496,000 after purchasing an additional 10,000 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in DiaMedica Therapeutics by 11.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 187,465 shares of the company’s stock worth $1,550,000 after buying an additional 19,399 shares during the last quarter. Cetera Investment Advisers purchased a new position in DiaMedica Therapeutics during the 3rd quarter worth approximately $280,000. AWM Investment Company Inc. grew its stake in DiaMedica Therapeutics by 80.8% during the 3rd quarter. AWM Investment Company Inc. now owns 65,097 shares of the company’s stock worth $538,000 after buying an additional 29,097 shares during the last quarter. Finally, Tocqueville Asset Management L.P. acquired a new position in DiaMedica Therapeutics during the third quarter worth approximately $332,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

About DiaMedica Therapeutics

(Get Free Report)

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.

Recommended Stories

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.